Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Illumina Ventures
BioCentury | Jan 15, 2025
Emerging Company Profile
Mursla: Using extracellular vesicles to detect cancer
Led by former banker Pierre Arsène, the start-up’s first goal is surveillance of cirrhosis patients at risk of liver cancer
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Oct 6, 2023
Regulation
Oct. 5 Quick Takes: FDA panel declines to back Lumakras
Plus: Mirati rises after Sanofi takeout rumor circulates, ODAC panel and updates from Kyowa Kirin, AbbVie, Evotec, FDA, Precede and more
BioCentury | Oct 5, 2023
Regulation
Oct. 4 Quick Takes: FDA’s ODAC backs US WorldMeds’ eflornithine for neuroblastoma
Plus: ClavystBio launches space for start-ups in Singapore and updates from Novavax, Iambic, Sandoz, Shorla and more
BioCentury | Sep 19, 2023
Product Development
Sept. 18 Quick Takes: Anthos’ mAb meets Phase II bleeding endpoint
Plus: Priority review for Orchard’s ex vivo gene therapy and more from BioNTech, Broken String and FDA
BioCentury | Aug 18, 2023
Finance
Aug. 17 Quick Takes: China tools play Sangon attracts Novo Holdings in $290M round
Plus: Appeals court restricts mifepristone access and updates for Lightcast, AbbVie, Regeneron, Selecta, the IRA
BioCentury | Jun 21, 2023
Emerging Company Profile
Attovia: improving affinity and specificity using linked nanobodies
Alamar spinout Attovia is linking single heavy chain antibody pairs to double down on difficult therapeutic targets for cancer and immune diseases
BioCentury | Jun 2, 2023
Emerging Company Profile
Actym: programming microbes to treat solid tumors
Backed by Boehringer Ingelheim and Panacea, Actym is engineering microbes to enable safe, systemic delivery
BioCentury | Apr 27, 2023
Finance
April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies
Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
Items per page:
1 - 10 of 54